Sophiris again amends NASDAQ listing, follow-on

Sophiris Bio Inc. (TSX:SHS) amended its plans to list on NASDAQ late Thursday and said it is now aiming to raise $65 million through the sale of 13 million shares at about $5 in a follow-on underwritten by Citigroup; Leerink; Stifel; and Lazard. Earlier this month, Sophiris said it hoped to sell 5 million shares at about $13 in the offering. The company first announced plans to list on NASDAQ and raise up to $74.8 million in a follow-on in February. ...